NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

Molecular Metabolism is a premier, open-access journal published by Elsevier, dedicated to advancing the understanding of metabolic processes at the molecular level. With an ISSN of 2212-8778 and a proud presence in Germany, the journal has made significant contributions to the fields of Cell Biology and Molecular Biology, consistently achieving a Q1 ranking in both categories as of 2023. The journal’s scope encompasses cutting-edge research that explores metabolic pathways, their regulation, and implications for human health, underscoring the interplay between metabolism and various biological functions. Researchers and professionals benefit from the journal’s robust visibility, as it ranks #40 among 410 journals in Molecular Biology and #35 among 285 in Cell Biology according to Scopus metrics, placing it in the top 10 percentile in its field. With open access since 2012, Molecular Metabolism ensures that groundbreaking research is available to all, fostering a collaborative and inclusive academic environment. Its commitment to excellence and accessibility makes it an invaluable resource for those invested in metabolic research.

Nature Metabolism, published by NATURE PORTFOLIO, is a leading journal dedicated to advancing the field of metabolic research and its implications across various biological systems. Since its inception in 2019, this esteemed journal has rapidly established itself as a vital resource for researchers, professionals, and students alike, reflecting its prominence through a prestigious Q1 ranking in several key categories including Cell Biology, Endocrinology, Diabetes and Metabolism, Internal Medicine, and Physiology. With an impressive Scopus ranking, underscoring its impact in Medicine and Biochemistry disciplines, Nature Metabolism offers an exceptional platform for disseminating high-quality research that explores the intricate mechanisms of metabolism and its association with health and disease. Although currently not open access, it continues to gain visibility and appreciation within the scientific community, ensuring that groundbreaking findings reach interested audiences globally from its hub in Berlin, Germany. Whether you are an experienced researcher or an aspiring student, Nature Metabolism serves as an invaluable asset in navigating the complexities of metabolic science.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

PPAR Research, an esteemed journal published by HINDAWI LTD, specializes in the rapidly evolving fields of drug discovery and pharmacology, contributing significantly to the body of research surrounding peroxisome proliferator-activated receptors (PPARs) and their roles in various biochemical processes. With an open access policy implemented since 2006, the journal ensures that its high-quality content is readily available, promoting widespread dissemination of knowledge. Currently ranked in the Q2 category for both Drug Discovery and Medical Pharmacology, it boasts a respectable position within the scientific community, evidenced by its Scopus rankings. PPAR Research serves as an essential resource for researchers, professionals, and students looking to advance their understanding of PPAR biology and its implications in therapeutic development. The journal's commitment to excellence and accessibility makes it a key player in supporting innovative research and critical discussions in the life sciences.

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Cell Communication and Signaling is a premier peer-reviewed journal published by BMC that has made significant contributions to the fields of biochemistry, cell biology, and molecular biology since its establishment in 2003. As an open access journal, it offers unrestricted access to high-quality research, fostering collaboration and innovation among scientists around the globe. The journal is distinguished by its Q1 ranking in all three relevant categories for 2023, underscoring its critical role in advancing the understanding of cellular communication mechanisms and signaling pathways. Positioned within the United Kingdom, Cell Communication and Signaling has been an invaluable resource for researchers, professionals, and students alike, ensuring that the latest findings are accessible to a diverse range of audiences. With an impressive Scopus ranking—placing it in the top percentiles within its subject areas—this journal continues to set the standard for excellence in the pursuit of understanding complex cellular interactions.

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.